UPCI Melanoma Researchers Present Findings at Annual Meeting of American Society of Clinical Oncology
CHICAGO, June 5 – Researchers from the University of Pittsburgh Cancer Institute (UPCI) Melanoma Program, led by John M. Kirkwood, M.D., will present findings from seven studies at the American Society of Clinical Oncology annual meeting, June 4 to 8, at McCormick Place in Chicago.
Highlights of their findings include:
Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Metastatic Melanoma
Sponsored by the Southwest Oncology Group
Researchers continue to seek effective treatment options for advanced melanoma patients. This randomized, phase II trial compared a combination of chemotherapies designed for patients with genetic mutations that cause cancer cells to resist treatment. The combination of sorafenib with temsirolimus or tipifarnib did not improve disease response, but researchers believe that newer, molecularly targeted approaches and combinations still hold the greatest promise for future treatments. Abstract 8502
# # #
About University of Pittsburgh Cancer Institute (UPCI)
As the only NCI-designated comprehensive cancer center in western Pennsylvania, UPCI is a recognized leader in providing innovative cancer prevention, detection, diagnosis, and treatment; bio-medical research; compassionate patient care and support; and community-based outreach services. UPCI investigators are world-renowned for their work in clinical and basic cancer research.
http://www.upmc.com/mediarelations
CONTACT: Courtney McCrimmon, McCrimmonCP@upmc.edu
PHONE: (412) 715-8894
CONTACT: Wendy Zellner, ZellnerWL@upmc.edu
PHONE: (412) 586-9777
Tags: